NCT06383767View on ClinicalTrials.gov

A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

378

Participants

Timeline

Start Date

July 11, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

July 31, 2028

Conditions
Metastatic Breast Cancer
Interventions
DRUG

ESG401

IV infusion on day 1,8, and 15 of each 28 day cycle

DRUG

Eribulin, capecitabine, gemcitabine or vinorelbine (Treatment of Physician's Choice)

Eribulin, capecitabine, gemcitabine or vinorelbine

Trial Locations (1)

100021

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY